Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy of MaaT013 As Salvage Therapy in Acute GVHD Patients with Gastrointestinal Involvement, Refractory to Ruxolitinib; a Multi-center Open-label Phase III Trial.

NCT04769895 is registered in ClinicalTrials.gov with MaaT Pharma as lead sponsor.

NCT NCT04769895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04769895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy of MaaT013 As Salvage Therapy in Acute GVHD Patients with Gastrointestinal Involvement, Refractory to Ruxolitinib; a Multi-center Open-label Phase III Trial.
Lead sponsor
MaaT Pharma
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 25, 2022
Completion date
November 30, 2025
Enrollment
66 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft versus host disease in intestine, steroid refractory gvhd